Patents by Inventor Krzysztof J. Grzegorzewski

Krzysztof J. Grzegorzewski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SPECIFIC ANTI-CD38 ANTIBODIES FOR TREATING HUMAN CANCERS
    Publication number: 20190284294
    Abstract: The present disclosure concerns an antibody that specifically binds CD38 which is capable of killing a CD38+ cell by induction of apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose of about 20 mg/kg or below. In one embodiment, the medicament is for treating CD38+ multiple Myeloma in humans.
    Type: Application
    Filed: November 21, 2018
    Publication date: September 19, 2019
    Inventors: Antoine DESLANDES, Krzysztof J. GRZEGORZEWSKI, Marie-Laure OZOUX, Blake TOMKINSON
  • SPECIFIC ANTI-CD38 ANTIBODIES FOR TREATING HUMAN CANCERS
    Publication number: 20180022814
    Abstract: The present disclosure concerns an antibody that specifically binds CD38 which is capable of killing a CD38+ cell by induction of apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose of about 20 mg/kg or below. In one embodiment, the medicament is for treating CD38+ multiple Myeloma in humans.
    Type: Application
    Filed: April 5, 2017
    Publication date: January 25, 2018
    Inventors: Antoine Deslandes, Krzysztof J. Grzegorzewski, Marie-Laure Ozoux, Blake Tomkinson
  • SPECIFIC ANTI-CD38 ANTIBODIES FOR TREATING HUMAN CANCERS
    Publication number: 20150118251
    Abstract: The present disclosure concerns an antibody that specifically binds CD38 which is capable of killing a CD38+ cell by induction of apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose of about 20 mg/kg or below. In one embodiment, the medicament is for treating CD38+ multiple Myeloma in humans.
    Type: Application
    Filed: October 31, 2014
    Publication date: April 30, 2015
    Inventors: Antoine Deslandes, Krzysztof J. Grzegorzewski, Marie-Laure Ozoux, Blake Tomkinson
  • Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (MPIF-1)
    Publication number: 20030114379
    Abstract: There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3 and chemokine &bgr;8 (CK&bgr;8 or ckb-8)), as well as MPIF-1 polypeptide itself, as are vectors, host cells and recombinant methods for producing the same.
    Type: Application
    Filed: October 2, 2002
    Publication date: June 19, 2003
    Applicant: Human Genome Sciences, Inc.
    Inventors: Haodong Li, Steven M. Ruben, Krzysztof J. Grzegorzewski, Craig A. Rosen, Vikram Patel, Reinder L. Gentz